(SLGL) – Press Releases
-
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
-
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
-
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
-
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
-
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
-
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
-
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
-
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
-
Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
-
Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
-
Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
-
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development
-
Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Galderma Launches EPSOLAY® Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea
-
Sol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference
-
Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference
-
Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®
-
Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®
-
Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments
-
Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA
-
Galderma Launches TWYNEO® Cream, the First Ever Tretinoin and Benzoyl Peroxide Combination to Treat Facial Acne
-
Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference
-
Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®
-
Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments
-
Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference
-
Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million
-
Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference
-
Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference
-
Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments
-
Sol-Gel Technologies Announces FDA Approval of TWYNEO®
-
Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021
-
Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021
-
Sol-Gel Announces Pipeline Update and Future Development Plans
-
Sol-Gel Announces Pipeline Update and Future Development Plans
-
Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States
-
Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference
-
Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference
-
Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update
-
Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®
-
Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update
-
Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global Life Sciences Conference
-
Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Conference
-
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo® for the Treatment of Acne Vulgaris
-
Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update
-
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020
Back to SLGL Stock Lookup
